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Abstract
Sarcoidosis is a complex, multi-organ granulomatous disease with a likely genetic component. West African ancestry confers
a higher risk for sarcoidosis than European ancestry. Admixture mapping provides the most direct method to locate genes
that underlie such ethnic variation in disease risk. We sought to identify genetic risk variants within four previously-
identified ancestry-associated regions—6p24.3–p12.1, 17p13.3–13.1, 2p13.3–q12.1, and 6q23.3–q25.2—in a sample of 2,727
African Americans. We used logistic regression fit by generalized estimating equations and the MIX score statistic to
determine which variants within ancestry-associated regions were associated with risk and responsible for the admixture
signal. Fine mapping was performed by imputation, based on a previous genome-wide association study; significant
variants were validated by direct genotyping. Within the 6p24.3–p12.1 locus, the most significant ancestry-adjusted SNP
was rs74318745 (p = 9.4*10211), an intronic SNP within the HLA-DRA gene that did not solely explain the admixture signal,
indicating the presence of more than a single risk variant within this well-established sarcoidosis risk region. The locus on
chromosome 17p13.3–13.1 revealed a novel sarcoidosis risk SNP, rs6502976 (p = 9.5*1026), within intron 5 of the gene X-
linked Inhibitor of Apoptosis Associated Factor 1 (XAF1) that accounted for the majority of the admixture linkage signal.
Immunohistochemical expression studies demonstrated lack of expression of XAF1 and a corresponding high level of
expression of its downstream target, X-linked Inhibitor of Apoptosis (XIAP) in sarcoidosis granulomas. In conclusion, ancestry
and association fine mapping revealed a novel sarcoidosis susceptibility gene, XAF1, which has not been identified by
previous genome-wide association studies. Based on the known biology of the XIAP/XAF1 apoptosis pathway and the
differential expression patterns of XAF1 and XIAP in sarcoidosis granulomas, we suggest that this pathway may play a role in
the maintenance of sarcoidosis granulomas.
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Introduction
Sarcoidosis is a granulomatous, inflammatory disease of
uncertain etiology. The lung is the most commonly affected
organ, with 90% of cases presenting pulmonary involvement [1].
The development and accumulation of granulomas—compact,
centrally-organized collections of macrophages and epithelioid
cells encircled by lymphocytes—constitute the fundamental
abnormality in sarcoidosis. Despite the lack of a known etiologic
agent, epidemiologic and molecular studies indicate that sarcoid-
osis is an antigen-driven disease[2], with a Th1- and possibly
Th17-mediated immune response[3]. Although patients with lung
involvement may not progress sequentially through the Scadding
disease stages (I–IV) [4], pulmonary sarcoidosis often begins as
asymptomatic bihilar lymphadenopathy (Stage I) and may
progress to overt pulmonary involvement, as seen in Stages II
and III. Stage IV sarcoidosis is characterized by pulmonary
fibrosis and lack of immune cell activity; although death from
sarcoidosis is rare, Stage IV cases have lower rates of survival [5].
Populations of West African descent have higher sarcoidosis
incidence than European populations; the adjusted annual
incidence among African Americans is roughly three times that
of White Americans (35.5/100,000 versus 10.9/100,000) [6].
African ancestry is also associated with more chronic and severe
disease [7,8]. In recently admixed populations (such as African
Americans), mapping by admixture linkage disequilibrium takes
advantage of such differences in disease susceptibility between
ancestral populations to identify genetic loci associated with both
disease and ancestry [9,10]. Current admixture mapping methods
permit estimation of local ancestry (defined as zero, one, or two
copies of a given ancestral origin) over a dense set of genetic
markers [11]. In addition to refining an ancestry signal, these
methods of local ancestry estimation also permit testing whether
variation at a single SNP accounts for a local ancestry signal [11].
Compared to the genome-wide association approach, association
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testing within regions of admixture linkage improves statistical
power by greatly limiting the number of tests performed and
allows for discovery of monomorphic variants in parent popula-
tions.
In our previous admixture mapping scan for sarcoidosis risk loci
in African Americans, we identified nine regions that suggested
admixture linkage to both West African as well as European alleles
[12]. Upon further analysis that included additional related
subjects, four of these nine regions increased in statistical
significance, while the remaining five regions decreased in
significance [13]. The strongest admixture signal was located at
chromosome 6p24.3–12.1, the locus encompassing the human
leukocyte antigen (HLA) region, which is known to be associated
with sarcoidosis risk [14]. The most significant novel risk locus was
found at chromosome 17p13.3–13.1 [12]. Both loci showed an
association between increased African ancestry and sarcoidosis
risk. Three additional regions (2p12–q12.3, 10p12.2–10q11.23,
and 16q22.1–16q23.2) showed suggestive heterogeneity in ances-
try linkage between cases whose disease resolved within two years
of diagnosis compared to those with fibrotic lung disease (Stage
IV). In our original genome-wide association study (GWAS),
genome-wide significant effects were confined to HLA region [14].
The goal of the present study was to leverage the independent
local ancestry information used by admixture mapping to identify
specific SNP(s) most likely to account for the observed ancestry
signal within the HLA region. In addition, we sought to fine map
novel regions missed in the GWAS to guide gene sequencing and/
or functional studies of additional putative risk genes and genes
associated with lung fibrosis, which was not a component of the
original GWAS. To quantify the contribution of local West
African ancestry to sarcoidosis risk, we used the genome-wide
complex trait analysis (GCTA) approach to estimate the herita-
bility of sarcoidosis due to local ancestry across autosomes [15,16].
To achieve these goals, we used local ancestry and genotype
imputation based on data from our previous African American
GWAS of sarcoidosis risk.
Results
Fine mapping results for sarcoidosis risk and Scadding
stage IV regions
Table 1 displays results for markers within regions of sarcoidosis
ancestry risk linkage that displayed the most significant allelic
association, before and after adjustment for local ancestry. (A
complete list of association results with local ancestry-adjusted or -unadjusted
marker p-values,0.05 is displayed in Table S1.) Three of the four
admixture linkage regions (6p24.3–12.1, 17p13.3–13.1, and 2p12–
q12.1) contained variants that were associated with sarcoidosis risk
at or below the suggestive level of genome-wide significance
(p = 1025).
The most significant SNPs within 6p24.3–12.1 were located
within or near the HLA-DRA gene (Figure 1). Of these, the most
significant was rs74318745, located within intron 4 of HLA-DRA
(OR=0.69; 95% Confidence Interval (CI) 0.62–0.78;
p = 9.4*10211). Adjustment for local ancestry showed no con-
founding (OR=0.69; CI 0.62–0.77; p = 4.5*10211). Consistent
with this finding, the MIX score result for this SNP (p = 7.9*10212)
was the most significant in the region, indicating that it is the
variant most likely to explain the admixture linkage signal.
Further, the DIFF score p-value (0.051) suggests that one or more
additional SNPs in this region contribute to the admixture linkage,
as this p-value falls slightly above the nominal significance
threshold of 0.05.
SNP rs7431874 is in perfect linkage disequilibrium (r2 = 1) with
the SNP rs2227139, the most significant SNP identified within the
HLA region in our GWAS [14]. In that study, subsequent
conditional analyses revealed four additional independent variants
(SNPs rs146146117 HLA-DQA1, rs9461776 HLA-DRB1, rs715299
NOTCH4, and rs9272320 HLA-DQA1) associated with sarcoidosis
risk in the HLA class II region at the suggestive GWA significance
threshold. In the current study, all five variants had DIFF score
p-values,0.06, suggesting that none of the variants alone explain
the admixture linkage signal. Consistent with this finding, the case-
control local ancestry association remained significant after
adjustment for each SNP (all ancestry association p-values,0.03).
However, adjustment for all five SNPs resulted in a non-significant
ancestry association (p= 0.25).
The second most significant admixture linkage region was
17p13.3–13.1, with multiple SNPs associated with sarcoidosis risk
and no evidence of confounding by local ancestry. The most
significant of these was the imputed SNP rs6502976 (OR=0.74;
CI 0.64–0.84; p-value = 9.5*1026), located within intron 5 of the
X-linked inhibitor of apoptosis associated factor 1 (XAF1) gene.
This finding was supported by the directly-genotyped SNP
rs9891567 (Figure 2; OR=0.79; CI 0.67–0.87 p-value
= 3.2*1026), which is in linkage disequilibrium (LD; r2 = 0.81).
Direct genotyping of rs6502976 demonstrated high concordance
(98%, Table S2) with the imputed calls. Adjustment for local
ancestry had little effect on the odds ratio (OR=0.74; CI 0.63–
0.86; p = 1.2*1024). The MIX score result (p = 7.9*1025) indicated
that this variant was likely to explain the admixture linkage; the
corresponding DIFF result (p = 1.00) indicated that it was likely the
only one explaining the admixture linkage result. Consistent with
this finding, odds ratios were similar across strata of individuals
with zero (OR=0.84, CI 0.45–1.54), one (OR=0.78, CI 0.59–
1.02), and two (OR=0.74, CI 0.61–0.91) African alleles.
Among the three non-HLA admixture linkage loci studied, the
most significant association both before and after adjustment for
local ancestry (Table 1) was identified within the 2p13.3–2q12.1
locus at the imputed SNP rs62158012, located within an intron of
the mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosa-
minyltransferase, isozyme A (MGAT4A) gene. Similar to the other
variants in Table 1, the odds ratio for SNP rs62158012 shows no
confounding by local ancestry, and the MIX (p= 2.5*1025) and
DIFF (p = 0.64) scores suggest that this variant explains the
ancestry signal. Among the genotyped SNPs, rs12467276 is in
highest pairwise LD (r2 = 0.44) with rs62158012 and consistently
reflects its association with risk (OR=1.36; CI 1.16–1.59;
p = 1.4*1024). This region overlaps with 2p12–q12.3, the region
of admixture linkage to Scadding stage IV disease. Before
adjustment for local ancestry, rs62158012 was associated with
risk of stage IV disease (OR=2.05, CI 1.38–3.05, p= 3.9*1024).
After adjustment for local ancestry, the odds ratio suggests that an
additional marker exists in this region that may explain the
admixture linkage to Scadding stage IV disease (OR=1.80, CI
1.20–2.71, p = 0.005).
Table 2 contains the association results for markers within
regions of Scadding stage IV ancestry linkage. The variant most
likely to explain the signal in the 2p13.3–2q12.1 region was
imputed SNP rs6547087, which is located within a large intergenic
region (Table 2). The MIX (p= 2.2*1024) and DIFF (p= 1.00)
scores suggest that there are no additional variants likely to explain
the admixture linkage in this region. The genotyped SNP
rs2091716 was in high pairwise LD (r2 = 0.97) with rs6547087;
its effect (OR=2.02; CI = 1.44–22.83; p= 4.1*1025) was consis-
tent with it. Among the three regions in our original admixture
analysis that were linked to radiographic Scadding stage IV
XAF1 and Sarcoidosis in African Americans
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disease, the 10p12.1–11.21 region displayed the highest level of
significance in both the unrelated and related analyses. Within this
region, SNP rs906233 displayed the most significant local ancestry
association (unadjusted OR=1.77; CI 1.38–2.27; p= 7.7*1026;
adjusted OR=1.70; CI 1.32–2.20; p= 4.8*1025). The MIX score
result (p = 3.8*1025) is consistent with this, and the corresponding
DIFF result (p = 0.141) suggests that there is not strong evidence
for additional variants within the region that account for this
signal. Like rs6547087 above, this variant is also located in a gene-
poor region; rs906233 is located 69kb upstream of the lysozyme-
like 2 (LYZL2) gene and 109 kb downstream of the mitogen-
activated protein kinase 8 (MAP3K8) gene. Among the three
Scadding stage IV admixture linkage regions, the most statistically
significant association was found in the 16q22.1–23.2 locus at the
imputed SNP rs12919626 (Table 2). This SNP is an intronic
variant within the fatty acid 2-hydroxylase (FA2H) gene. Among
the genotyped SNPs, rs11554620 is in highest pairwise LD
(r2 = 0.20) with rs12919626 and consistently reflect its association
with Stage IV disease (OR=1.35; CI 1.04–1.76; p= 0.024). While
there was no evidence of confounding by local ancestry at this
locus, the DIFF score (p = 0.004) suggests that at least one
additional variant associated with risk of Scadding stage IV disease
Table 1. Peak allelic associations within genomic regions of sarcoidosis ancestry linkage after adjustment for both global and local
West African ancestry and corresponding MIX score results.
Global Ancestry Adjusted
Global + Local Ancestry
Adjusted MIX
SNP,Allele1,Status2 Locus fCEU fAFR fAFF fUNF OR 95%CI P OR 95%CI P P
rs62158012, A/C,
imputed
Chr 2q11.2,
MGAT4A intron
0.27 0.01 0.09 0.06 1.70 1.38–2.09 6.7*1027 1.70 1.36–2.12 2.8*1026 2.5*1025
rs74318745, A/G,
genotyped
Chr 6p21.32,
HLA-DRA intron
0.51 0.42 0.42 0.51 0.69 0.62–0.78 9.4*10211 0.69 0.62–0.77 4.5*10211 7.9*10212
rs78512816, C/T,
genotyped
Chr 6q23.3, 22 kb
downstream of
OLIG3
---3 0.07 0.03 0.05 0.58 0.44–0.76 9.5*1025 0.59 0.45–0.78 1.8*1024 9.8*1025
rs6502976, C/G,
imputed
Chr 17p13.1,
XAF1 intron
0.65 0.09 0.18 0.23 0.74 0.64–0.84 9.5*1026 0.74 0.63–0.86 1.2*1024 7.9*1025
Abbreviations: fCEU: frequency of modeled allele in HapMap Northern and Western European ancestry population; fAFR: frequency of modeled allele in HapMap Yoruban
African ancestry population; fAFF: frequency of modeled allele in sarcoidosis-affected individuals; fUNF: frequency of modeled allele in unaffected individuals; OR: odds
ratio; 95%CI: 95% confidence interval; P: p-value; MIX: MIXSCORE test.
1Minor allele in African Americans is bolded; modeled by generalized estimating equations adjusting for percent global West African ancestry and sex.
2‘‘Imputed’’ Indicates a SNP that was imputed rather than directly genotyped. Accuracy of imputation was assessed for SNPs with p-values,1025 in a sub-sample, and
for each SNP; agreements overall and by genotype are reported in Table S2. Overall accuracy of imputation was 98.7% (rs62158012) and 98.0% (rs6502976).
3No carriers of the T allele of rs78512816 exist within HapMap and 1000 Genomes Project European populations.
doi:10.1371/journal.pone.0092646.t001
Figure 1. Plot of association test results across chromosome
6p12.1–24.3. The –log10 (P-values) plotted are from SNP association
tests adjusted for global percent African ancestry and sex. Association
p-values plotted with squares indicate genotyped SNPs; circles indicate
imputed SNPs. Shading indicates linkage disequilibrium (LD) r2 values
between SNP rs74318745 and the remaining SNPs in the region (strong
LD: r2$0.8 (red); moderate LD: r2$0.5 (orange); weak LD: 0.8.r2.0.5
(yellow); not in LD: r2,0.2 (white)) were estimated in a sample of 250
unrelated African American controls from the current study. Recombi-
nation rates are displayed in blue and are based on the average across
the phase II International HapMap reference populations.
doi:10.1371/journal.pone.0092646.g001
Figure 2. Plot of association test results across chromosome
17p13.1–13.3. The –log10 (P-values) plotted are from SNP association
tests adjusted for global percent African ancestry and sex. Association
p-values plotted with squares indicate genotyped SNPs; circles indicate
imputed SNPs. Shading indicates linkage disequilibrium (LD) r2 values
between SNP rs6502976 and the remaining SNPs in the region (strong
LD: r2$0.8 (red); moderate LD: r2$0.5 (orange); weak LD: 0.8.r2.0.5
(yellow); not in LD: r2,0.2 (white)) were estimated in a sample of 250
unrelated African American controls from the current study. Recombi-
nation rates are displayed in blue and are based on the average across
the phase II International HapMap reference populations.
doi:10.1371/journal.pone.0092646.g002
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exists in this region.
To determine whether additional variants could explain the
admixture linkage at 16q22.1–23.2 locus, a forward model
selection procedure was applied, and the resulting variants are
also reported in Table 2. Conditioning on rs12919626, the next
most significant SNP in the region is rs145044562 (p= 5.1*1025),
which is located within an intron of the WW domain-containing
oxidoreductase (WWOX) gene. Similar to SNP rs12919626, the
DIFF score p-value (p = 0.006) suggests that it is not the only SNP
in the region that explains the admixture signal. Further,
conditioning on both rs12919626 and rs145044562 revealed a
second SNP (rs1077963) within an intron of WWOX that was
associated with risk of Scadding stage IV disease. The DIFF score
for SNP rs1077963 (p= 1.0) suggests that this SNP explains the
admixture linkage in this region. Consistent with this finding, the
case-control local ancestry association remained significant after
adjustment for both rs12919626 and rs145044562 (ancestry
association p-values,0.005) but was rendered non-significant
(p = 0.62) after adjustment for rs1077963.
In silico expression quantitative trait locus (eQTL) results
for XAF1 SNPs
Because the SNPs most likely to explain the ancestral linkage
signals with overall risk and Scadding stage IV disease are found in
non-coding or intergenic regions, we used existing eQTL studies
to further investigate their possible function. Using the GENe
Expression Variation (GeneVar) application [17], we summarized
results from two studies of multiple cell types: an eQTL study of
171 female identical twins [18], and a genome-wide study of
eQTLs in cord blood samples of 75 individuals [19]. Of the SNPs
most likely to explain local ancestry signals, only the SNPs in XAF1
showed evidence of being cis-acting eQTLs. Results (Table 3)
show suggestive evidence for SNP rs6502976 as an eQTL for
XAF1 through linkage disequilibrium with two other SNPs
(rs9891567 and rs1533031) that have been directly genotyped in
studies of European individuals; both of these SNPs are also
associated with risk of sarcoidosis (Figure 2). The pattern of
association between these SNPs and XAF1 expression is consis-
tent, with the protective allele at each SNP associated with
decreased expression of XAF1. Figures S1 and S2 show XAF1
expression levels by genotype at SNPs rs1533031 and rs9891567,
respectively. These findings are also supported by another recent
study [20], where rs9891567 was the most significant cis-eQTL for
XAF1 transcriptional expression in both B-cells (p = 4.4*10220)
and monocytes (p = 1.1*10212).
Immunohistochemistry (IHC) studies of XAF1 and XIAP
To further explore XAF1 as a novel sarcoidosis candidate
susceptibility gene in African Americans, we conducted IHC
protein expression studies for both the XAF1 and X-linked
inhibitor of apoptosis (XIAP) genes in granulomatous sarcoidosis-
affected tissue. We stained thirteen sarcoidosis-affected tissue
specimens (7 lung, 2 lymph nodes, 1 liver, 1 spleen, 2 skin) from
twelve African American patients. Nuclear and cytosolic staining
for XIAP was positive in all specimens whereas XAF1 staining was
consistently negative or very weak. Representative IHC results for
both XAF1 and XIAP are shown in Figure 3. XAF1 expression
(Figure 3a–d) is present at the periphery of the specimen, in
histologically normal cells distal to granulomas; increased XIAP
staining (3e–f) clearly demarcates the sarcoidosis granulomas.
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Estimation of heritability of sarcoidosis risk due to local
ancestry overall and by radiographic phenotypes.
To quantify the contribution of local West African ancestry to
sarcoidosis risk, we used the GCTA approach to estimate disease
heritability due to local ancestry across autosomes [15,16]. The
count of zero, one, or two West African alleles was used in place of
the actual genotype to compute the covariance between individ-
uals and to estimate the heritability of sarcoidosis (overall and by
radiographic phenotype) due to local ancestry (Table 4). For
comparison, the GCTA estimates of the additive genetic effects
due to common SNPs (.1% minor allele frequency) are also
provided. We observed that 15% of the variation in sarcoidosis
genetic risk is due to local ancestry, compared to a heritability of
26% due to the additive effects of common variation. Stratifying
the sarcoidosis cases by radiographic phenotype increased the local
ancestry heritability point estimate for resolving disease (23%).
The local ancestry heritability for Scadding stage IV disease was
also higher (26%) than that for stage I–III (18%) disease.
To estimate the effects on heritability of the three admixture
linkage regions (6p24.3–12.1, 17p13.3–13.1, and 2p12–q12.1)
containing variants associated with sarcoidosis risk at or above the
suggestive level of genome-wide significance (p= 1025), the local
ancestry estimates for these regions were each removed, and the
heritability estimates were recalculated (Table 4). Unsurprisingly,
the largest effect on the overall heritability estimate resulted from
removal of the 6p24.3–12.1 region. Local ancestry over this region
accounted for an approximately 20% reduction in the heritability
estimate, indicating that ,80% of the heritability to risk due to
local ancestry is attributable genetic variation residing in areas of
the genome outside of the broader major histocompatibility
complex region. Removal of the other admixture-linked loci had
less of an effect (,0.2% reduction). For subgroups of radiographic
phenotypes, removal of local ancestry at the 6p24.3–12.1 region
resulted in lower heritability estimates for resolving (35%
reduction) and persistent Scadding stage I–III (39% reduction)
disease (Table 4); notably, however, removal of this region had
little effect heritability estimate for persistent Scadding stage IV
disease (Table 4).
Discussion
Sarcoidosis incidence varies across populations of different
ancestry, even within common geography, and is more common
among people of West African ancestry. We have previously used
admixture mapping to show that local West African ancestry is
associated with disease risk in African Americans [12,13]. In this
study, we focused on previously-identified admixture regions,
using genotyping data from our recently-published GWAS of
sarcoidosis [14] and genotype imputation within the prioritized
regions.
The SNP with the lowest p-value at the most significant novel
admixture locus (17p13.3–13.1)—rs6502976—is located within
intron 5 of the XAF1 gene, a novel candidate risk gene for
sarcoidosis. XAF1 is a negative regulator of XIAP, upregulating
apoptosis by antagonizing the anti-caspase activity of XIAP [21].
XAF1 also antagonizes the cellular inhibitor of apoptosis genes C-
IAP1 and C-IAP2 [22], and may sensitize cells to Fas-mediated
apoptosis [23], which is thought to play a role in sarcoidosis
[24,25]. In IHC expression studies, we observed lack of XAF1
expression in sarcoidosis affected tissues and higher XIAP
expression within sarcoid granulomas than in surrounding tissues.
While we were unable to relate XAF1/XIAP expression levels to
genotype, the staining patterns we observed suggest that inhibition
of apoptosis as a result of low XAF1/high XIAP expression may
influence granuloma formation or maintenance. Our analysis
showed that rs6502976 was likely the only SNP responsible for the
admixture linkage signal within this region. Further, eQTL
analyses suggest a potential functional role for this SNP in the
transcriptional expression of XAF1, which may affect XAF1
protein levels. Because XAF1 protein expression was low to absent
in sarcoidosis-affected tissues, we hypothesize that any role
rs6502976 plays in disease etiology would be early in pathogenesis,
before sarcoidosis granulomas are histologically detectable.
Fine mapping within the HLA region identified an intronic
HLA-DRA variant—rs74318745—as the most significant SNP
within this region. In our GWAS, multiple genetically-identical
(r2 = 1) SNPs were significantly associated with sarcoidosis risk
[14], including a missense SNP (rs7192) in HLA-DRA that has been
associated with risk of both rheumatoid arthritis and systemic
lupus erythematosus [26], and a splice-acceptor variant (rs8084)
associated with rheumatoid arthritis [27,28]. Other genetically-
identical SNPs include rs3129889, associated with multiple
sclerosis [29], and rs2227139, associated with white blood cell
count [30]. However, additional results suggest that SNP
rs74318745 (or variants in high linkage disequilibrium) may not
completely explain the admixture linkage signal within the region.
This finding is consistent with our GWAS, which identified four
additional independent variants associated with sarcoidosis risk
within or near the genes HLA-DQA1, HLA-DRB1, and NOTCH4
[14]. This scenario is similar to the initial identification of the
prostate cancer admixture signal at 8q24 [31] and the subsequent
identification of multiple independently-associated variants within
this region of the genome via association mapping in additional
ethnically diverse populations [32].
Among the three non-HLA admixture regions associated with
risk of disease, the most significant SNP was located within the
MGAT4A gene on chromosome 2. In a gene expression study of
pulmonary sarcoidosis tissues and healthy lung specimens [33],
MGAT4A was up-regulated 1.66-fold (p = 0.0145, uncorrected for
multiple testing) in sarcoidosis tissue.
For the admixture regions associated with risk of Scadding stage
IV disease, the most significant SNP (rs12919626) was located
within the FA2H gene located at chromosome 16q23.1. This gene
catalyzes a critical hydroxylation step necessary for the formation
of 2-hydroxy fatty sphingolipids, believed to be involved in cell
signaling [34]. Increased FA2H gene expression has been observed
in injured lung tissue in rats [35,36]. As our results suggested that
more than one variant in the region was likely to explain the
admixture signal, analyses conditional on SNP rs12919626
revealed two variants associated with Scadding stage IV disease
within the WWOX gene, with one (rs1077963) being the most
likely candidate to explain the admixture linkage in the region. A
known tumor suppressor gene (42, 43), WWOX resides with the
second most common fragile site in the human genome [37,38].
This gene was also recently found to be associated with lung
function in a GWA meta-analysis [39], and a functional copy
number variant was associated with lung cancer risk in a Chinese
population [40].
While the peak SNP (rs906233) association at the 10p12.1–
11.21 Scadding stage IV admixture locus is located in an inter-
genic region, the genes flanking it have plausible roles in
sarcoidosis. The lysozyme-like 2 (LYZL2) gene is part of a family
of lysome-like genes that are bacteriolytic and play a protective
role in host defense [41]. Also, MAP3K8 is a gene known to
activate nuclear factor kappaB production, which is a master
regulator of genes involved in immune response [42].
Our local ancestry-based GCTA heritability results suggest that
variation in linkage disequilibrium with local West African
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ancestry explains a large proportion of the heritable component of
sarcoidosis risk among African Americans. Further, even after
removing the three risk-associated admixture loci, there remained
a sizable statistically significant proportion of variation in heritable
risk attributable to the remaining local ancestry. The heritability
analysis also showed that differences in local ancestry were
associated with persistent disease, especially persistent Scadding
stage IV disease, which is more prevalent among African
Americans. These findings suggest that significant differences exist
in the genetic architecture of sarcoidosis risk between African
Americans and European Americans. In particular, removal of the
local ancestry effect at the HLA region did not change the
heritability estimates for risk of Scadding stage IV disease; this
suggests that the variants in HLA region that explain the admixture
linkage peak reside in genes that affect disease susceptibility more
than disease progression.
The current study is not without limitations, the most notable
being the lack of validation for the association findings. While we
have validated the imputed variants using direct genotyping, the
variants associated with risk and Scadding stage IV disease will
need to be validated in additional association studies of sarcoidosis
in African Americans. Scadding staging was assessed with chest
roentgenograms. Although computed tomography is more sensi-
tive for detecting fibrotic changes in the lungs of sarcoidosis
patients [43], the number of missed Stage IV cases is likely small
[44]. Given the large number of Scadding Stage IV cases in our
analysis (n = 190), such misclassification would likely have nominal
effects on our results. Another limitation of the study is the lack of
direct genotyping of novel variants in the full sample and our
reliance on an imputation-based approach to fine map the selected
admixture loci. While additional sequencing in these regions
would be ideal, we believe we have identified the most likely
variants underlying the admixture signals in these regions—which
can be follow-up with targeted sequencing.
In summary, we offer initial evidence for several potential novel
non-HLA genes associated with sarcoidosis susceptibility and
severity in African Americans. Furthermore, our ancestry herita-
bility results suggest there is still undiscovered genetic variation
underlying disease risk linked with ancestry. Our results emphasize
that admixture mapping of ancestry-associated risk loci can
identify important risk variants that go undetected in GWAS.
Variation at the most promising novel sarcoidosis susceptibility
gene, XAF1, may explain in part why African Americans are at
increased risk for sarcoidosis. Validation studies of our XAF1
association in independent samples as well as additional XAF1
functional studies are needed to further validate and define the
role of this novel gene in sarcoidosis pathogenesis.
Materials and Methods
Ethics Statement
Table 5 describes our sample comprising 2,727 self-identified
African Americans (1,271 cases, 1,456 controls) from three
independent studies of sarcoidosis patients, family members, and
controls: 1) a case-control etiologic study of sarcoidosis (ACCESS)
[45]; 2) a multi-site affected-sibling pair sarcoidosis linkage study
[46]; 3) a nuclear family-based sample ascertained through a single
affected individual within the Henry Ford Health System in
Detroit, MI [47]; and 4) healthy controls from the Oklahoma
Medical Research Foundation (OMRF) Lupus Family Registry
and Repository in Oklahoma City, OK [48]. For each of these
studies, participants gave written informed consent to allow their
research material to be used in future genetic studies. Study
protocols were approved by the institutional review board of each
study site (Beth Israel Deaconess Medical Center, Boston, MA;
Cleveland Clinic, Cleveland, OH; Emory Healthcare, Atlanta,
GA; Georgetown University Medical System, Washington, DC;
HFHS, Detroit, MI; Johns Hopkins Hospital, Baltimore, MD;
Medical University of South Carolina, Charleston, SC; Mount
Sinai Hospital, New York, NY; National Jewish Hospital, Denver,
CO; University of Cincinnati Hospital, Cincinnati, OH; Univer-
sity of Iowa Health Care, Iowa City, IA; University of North
Carolina Medical Center, Chapel Hill, NC; University of
Pennsylvania Health System, Philadelphia, PA;). DNA specimens
were processed at OMRF.
Study Sample Ascertainment and Phenotyping
Sample ascertainment protocols and demographics have been
described previously [45,46,47]. Where possible, cases were
phenotyped as to the persistence or absence of radiographic
Table 3. Genevar results suggest SNP rs6502976* is an eQTL for XAF1.
Global Ancestry Adjusted XAF13
SNP (r2) 1 Alleles2 OR 95%CI P eQTL Study Cell Type Correlation P
rs9891567 0.80 A/G 0.76 0.67–0.87 3.2*1025 Multiple Tissue
Human Expression
Resource4
Lymphoblastoid cells 20.58 7.7*1028
Adipocytes 20.46 2.0*1025
Skin cells 20.50 4.2*1026
rs1533031 0.57 A/G 0.80 0.71–0.91 3.2*1024 Geneva Umbilical
Cord Bank5
Lymphoblastoid cells 20.39 5.0*1024
T-cells 20.36 1.6*1023
Fibroblasts 0.02 0.85
Abbreviations: r2: linkage disequilibrium r2 measure; OR: odds ratio; 95%CI: 95% confidence interval; P: p-value; Correlation: Pearson correlation coefficient.
1Linkage disequilibrium r2 measure with rs6502976 in 250 unrelated African American controls from this study; SNP rs6502976 was not genotyped in either study.
2Minor allele in African Americans bolded; modeled by generalized estimating equations adjusting for percent global West African ancestry and sex.
3Pearson correlation values for genotype by XAF1 expression level (Illumina probe identifier ILMN_2370573); the direction of the correlation corresponds to an
increasing numbers of the minor allele in African Americans, which is the allele that is associated with sarcoidosis risk reduction.
4Nica et al 2011. Correlation results reported for twin 1; results were consistent for twin 2.
5Dimas et al 2009. SNP rs9891567 was not genotyped as part of this study.
doi:10.1371/journal.pone.0092646.t003
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evidence for lung disease two years after date of diagnosis. The
procurement of these data was done retrospectively, except for
cases enrolled during the first two years of the ACCESS study,
when study protocol dictated a two-year follow-up exam [49]. For
cases presenting with Scadding stage IV chest radiographs
(evidence of lung fibrosis or scarring), no follow-up chest x-ray
was needed for phenotyping (as stage IV x-ray indicates
permanent changes). Follow-up data were missing on 26.8% of
Figure 3. Representative pictures of XAF1 and XIAP staining of sarcoidosis-affected tissues. Panels A–D depict XAF-1 staining; panels
E–H depict XIAP staining. Panels A and B are bronchial mucosa; E and F are lung tissue; C and G are liver tissue; and D and H are skin tissue. In general,
XAF1 staining is negative in sarcoidosis-affected areas and limited to epithelial cells at the periphery (white arrows). XIAP staining was positive, with
greater intensity observed in non-caseating granulomas.
doi:10.1371/journal.pone.0092646.g003
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cases (340/1,271) due to the lack of necessary observation time
between diagnosis and study enrollment (n = 196) or missing chest
x-ray data at two or more after diagnosis (n = 144).
Genotyping and imputation methods
Genotyping was performed at OMRF using the Illumina (San
Diego, CA) HumanOmni1 Quad array for ,1.1 M SNPs as part
of our prior genome-wide association study [14]; details of
genotyping and quality control have been previously described.
Briefly included SNPs met the following quality control criteria:
well-defined cluster plots by visual inspections; call rate .95%;
minor allele frequency .0.01; Hardy-Weinberg proportion tests
P.0.0001 in cases and P.0.001 in controls; and differences in
case-control missingness P.0.001. Samples were removed from
analysis for the following: duplicate of another sample; cryptic
relatedness in independent datasets (proportion of alleles identical
by descent .0.25); low call rates (,90%); extreme heterozygosity
(.5 standard deviations from the mean); outlying principal
component values of population membership (calculated by
EIGENSOFT 3.0) [50] or global ancestry estimates (calculated
by ADMIXMAP [51,52]); discrepancy between reported sex and
genetic data.
Imputation was performed in 5 Mb bins across the genome
using the IMPUTE2 program [53] with 1000 Genomes Project
Phase I data (release June 2011) [54]—which contains haplotypes
derived from 1,094 individuals from Africa, Asia, Europe, and the
Americas—as the reference. IMPUTE2 was used to estimate the
posterior probabilities for the three possible genotypes (i.e. AA,
AB, and BB); a threshold of 0.9 was applied to these posterior
probabilities to produce the most likely genotypes. Imputed SNPs
with low imputation accuracy (information measure ,0.5 and
average maximum posterior genotype call probability ,0.9) or
failing the above quality control standards were removed to
minimize false positives.
We used imputation data for the four regions previously
associated with sarcoidosis risk (2p12–q12.1, 6p24.3–12.1,
6q23.3–25.2, and 17p13.3–13.1) and three regions associated
with Scadding stage IV disease (2p12–q12.3, 10p12.1–11.21, and
16q21–23.2). Table S2 displays the variants analyzed in each
region by genotype/imputation status. For imputed variants, we
include a summary of the imputations which exceeded a quality
threshold of 0.9; if the primary SNP in a region was imputed, we
confirmed accuracy through direct genotyping in a sub-sample of
individuals. There were four such SNPs. One (rs6502976) was
confirmed in a sub-sample of 426 individuals via sequencing, using
the Illumina (San Diego, CA) HiSeq2000 platform with Illumina
Pipeline software (version 1.7). The remaining three SNPs
(rs62158012, rs6547087, and rs12919626) were confirmed in a
sub-sample of 475 individuals using the TaqMan (Applied
Biosystems; Foster City, CA) allelic discrimination technology.
The agreement results (overall and by genotype) are presented in
Table S3 and indicated strong overall agreement with imputation
($98%) for all four SNPs. In the text, we also report the
association result for the genotyped SNP in highest pairwise LD
(as measured by r2) with the primary imputed SNP, where r2 was
calculated on a sub-sample of 250 unrelated African American
controls from this study.
Statistical Analysis
Our original admixture scan in a family-based sample identified
a total of twelve regions of interest: nine associated with risk of
disease and three associated with Scadding stage IV disease [12].
While this original analysis required selection of a single affected
Table 4. Heritability of sarcoidosis risk attributable to difference in local ancestry overall and by radiographic phenotypes.
Admixture Locus Removed1
All Autosomes 6p24.3–12.1 17p13.3–13.1 2p12–q12.1
Case Sub-groups N h2snp(SE) P h
2
anc(SE) P h
2
anc(SE) P h
2
anc(SE) P h
2
anc(SE) P
Overall2 689 0.26(0.07) 3.1*1025 0.15(0.04) 1.7*1024 0.12 (0.05) 0.02 0.15 (0.04) 1.8*1024 0.15(0.04) 1.8*1024
Radiographic Phenotypes
Resolved 226 0.53(0.15) 6.4*1025 0.23(0.08) 0.018 0.15(0.11) 0.177 0.23(0.08) 0.018 0.22(0.08) 0.022
All Persistent 463 0.28(0.08) 3.6*1024 0.17(0.04) 7.7*1024 0.14(0.05) 0.019 0.17(0.04) 7.5*1024 0.17(0.04) 7.1*1024
Scadding Stage I–III 322 0.28(0.11) 0.003 0.18(0.06) 0.002 0.11(0.08) 0.137 0.19(0.06) 0.002 0.19(0.06) 0.002
Scadding Stage IV 141 0.73(0.26) 0.003 0.26 (0.13) 0.066 0.27(0.13) 0.059 0.25(0.13) 0.077 0.27(0.13) 0.063
Note: Number of controls (n = 859) is the same across case analysis strata.
Abbreviations: N: number of cases; h2snp : proportion of additive genetic variance due the common variants (minor allele frequency $1%); h
2
anc :the proportion of the
additive genetic variance due to local West African ancestry; SE: standard error of h2anc ; P: p-value from a one-degree-of-freedom likelihood ratio test of the additive
genetic variance component.
1For these analyses, the corresponding admixture locus was removed to estimate the effect on the heritability estimate.
2These analyses were restricted to the subset of cases with a minimum of two years of follow-up.
doi:10.1371/journal.pone.0092646.t004
Table 5. Demographic and clinical characteristics of the
study sample.
Characteristic Affected (n=1,271)
Unaffected
(n =1,456)
Male n(%) 322 (25.3) 400 (27.5)
Percent African ancestry1 82.7 (9.4) 82.3 (11.1)
Radiographic phenotype2
Resolved 308 (33.1%) -
All persistent 623 (66.9%) -
Stage I–III 433 (69.5%) -
Stage IV 190 (30.5%) -
1Mean (standard deviation).
2Two-year follow-up chest x-ray and Scadding stage data n = 931.
doi:10.1371/journal.pone.0092646.t005
XAF1 and Sarcoidosis in African Americans
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e92646
individual from a family, for our analysis we used a new
application of ADMIXMAP that permits inclusion of all affected
family members to maximize statistical power [55]. Based on these
most recent admixture mapping results, fine-mapping was
restricted to those regions for which we could not exclude an
ancestry risk ratio of$2 or#0.5 (at a base-10 logarithm of the odds
admixture linkage score of -2, based on Hoggart et al’s exclusion-
mapping approach) [52]. This resulted in four regions associated
with sarcoidosis risk (2p12–q12.1: 71,618,323–106,550,301;
6p24.3–12.1: 18,069,307–44,536,360; 6q23.3–25.2: 134,423,766–
144,455,085; 17p13.3–13.1: 0–11,993,789) and three regions
associated with Scadding stage IV disease (2p12–q12.3:
80,127,798–112,062,746; 10p12.1–11.21: 24,687,265–35,999,931;
16q21–23.2: 65,774,387–79,031,043). The listed base-pair region
boundaries for association testing were determined by the first and
last marker with affected-only admixture p-values ,0.05.
The Local ancestry in AdMixed Populations (LAMP) method
[56,57] was used to estimate local ancestry—defined as the
probability of carrying zero, one, or two copies of west African (or
European) ancestral alleles at each SNP across the genome for
each individual; this method implements a sliding-window
approach, using allele frequencies of genome-wide markers in
the underlying ancestral populations to guide the estimation.
Estimates of ancestral allele frequencies for Illumina Omni-Quad
SNPs were derived from the HapMap [58] Yoruba and CEPH
European Utah catalogs, available through the Illumina iControl
database. The LAMP linkage disequilibrium threshold value for
this analysis was r2 = 0.1. Each window of local ancestry estimation
overlapped 20% of the markers in the adjacent windows, and a
constant recombination rate of 1028 per base pair was assumed.
Imputation of local ancestry for markers between non-linkage
disequilibrium-filtered markers was based on majority vote from
the local ancestry estimates of overlapping windows. For SNPs
imputed using the haplotypes from the 1000 Genomes Project
catalog and not included in the GWA genotyping, imputation of
local ancestry was based on the nearest genotyped SNP, with local
ancestry estimated via LAMP.
To use the complete sample of related and unrelated individuals
for association fine-mapping within regions of confirmed admix-
ture linkage, generalized estimating equations with logit link
function and an independence working correlation matrix were
used to compute the odds ratio for each SNP under a
multiplicative model (i.e. log additive), treating each family as a
cluster [59]. Because the local ancestry association signal may
confound these estimates, odds ratios were computed both with
and without adjustment for local ancestry; the degree of
confounding was calculated as the absolute difference between
adjusted and unadjusted log odds ratios, divided by the unadjusted
log odds ratio. Additionally, covariates for genome-wide West
African ancestry and sex were included in all models.
Next, markers with p-values ,0.05 that displayed minimal
confounding by local ancestry were tested using the MIX score
approach [11]. The MIX score tests the likelihood that a given
SNP explains an ancestry signal by constructing a test of the
ancestry odds ratio, parameterized by the allelic odds ratio
conditional on local ancestry and the underlying ancestral allele
frequencies. The null distribution of the MIX score is a one degree
of freedom chi-square and assumes that a single causal explains the
admixture linkage in a region. The degree to which this
assumption is met may be tested by a one degree of freedom
difference score (DIFF) between the MIX score and the sum of the
independent affected-only admixture score and the allelic SNP
association score, conditional on local ancestry signal; therefore, a
DIFF score p-value less than 0.05 indicates that there is likely more
than one SNP responsible for the local ancestry signal. Because the
MIX score assumes cases and control are unrelated, we performed
one hundred random, independent samples of 1,779 unrelated
subjects (933 cases, 846 controls); the SNP-specific MIX score
statistic was calculated as the average of these 100 samples.
This tiered analytical approach (i.e. refinement of region of the
genome where association testing is carried out based on affected-
only admixture mapping results) takes advantage of the indepen-
dence between the local ancestry and the marker genotype
associations conditional upon local ancestry, resulting in testing
many fewer marker genotype associations than in a traditional
genome-wide association study. Therefore, we emphasize only the
results of those variants that met the established genome-wide
significance threshold of 5*1028, the suggestive threshold of 1025,
and/or those most likely to explain the admixture linkage within
each region.
Additionally, we used the Genome-wide Complex Trait
Analysis (GCTA) program [15,16] to calculate a genome-wide
ancestry-based relationship matrix and to estimate from the
proportion of variance in liability to sarcoidosis that is explained
by additive effects of local ancestry. The same argument used by
Yang et al. [60] to estimate the genetic variance attributable to
SNPs can be used to estimate the genetic variance attributable to
local ancestry. For comparison, we also estimated the variance
attributable to genotyped autosomal SNPs. For both analyses, a
sarcoidosis prevalence of 1/1000 was used. To exclude the effects of
shared environment and alleles shared within families, the dataset
was restricted to individuals whose coefficient of relationship was
calculated from the pedigree to be less than 0.125 (equivalent to first
cousins) using a method described in Manichaikul et al [61] and
implemented in the KING relationship inference software [62]. The
analyses controlled for genome-wide ancestry proportion and sex.
Because African Americans are more likely to have persistent
sarcoidosis than Europeans Americans [7,8,63], we also investigated
whether radiographic phenotypes (resolution of disease after a
minimum of two years of follow-up; persistence of disease after this
time with Scadding stage IV disease; persistent disease without
Scadding stage IV; Scadding stage IV disease alone) differed in
heritability associated with local ancestry differences. In this
analysis, each category was compared to controls.
Immunohistochemistry
Specimens of lung, liver, spleen, lymph node, and skin tissue from
twelve African American patients with histologically-confirmed
sarcoidosis were procured from the HFHS Department of
Pathology. Each specimen was mounted on a slide, hemotoxin
and eosin stained, and examined by the study pathologist (DAC) for
presence of non-caseating granulomas. Rabbit polyclonal anti-
XAF1 antibody (ProSci Incorporated, Poway, CA, USA) was
diluted to 1:300. Goat polyclonal anti-XIAP antibody (R & D
Systems, Minneapolis, MN, USA) was diluted 1:100. Immunohis-
tochemical staining was performed using a standard avidin–biotin
complex method with a streptavidin–biotin–peroxidase kit (Ni-
chirei, Tokyo, Japan). Diaminobenzidine was used as a chromogen.
Supporting Information
Figure S1 Geneva Umbilical Cord Bank* eQTL results
for SNP rs1533031 and XAF1. Using the Genvar analysis tool,
expression levels of XAF1 (Illumina probe identifier
ILMN_2370573) are plotted by SNP rs1533031 genotype for
each individual (n = 75) by cell type in umbilical cord samples.
Abbreviations: r, Pearson correlation coefficient; P. *Dimas et al 2009.
(EPS)
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Figure S2 Multiple Tissue Human Expression Re-
source* eQTL results for SNP rs9891567 and XAF1.
Using the Genvar analysis tool, expression levels of XAF1
(Illumina probe identifier ILMN_2370573) are plotted by SNP
rs9891567 genotype for each identical twin (n = 171 female
identical twins) by tissue type. Abbreviations: r, Pearson correlation
coefficient; P. * Nica et al 2011.
(EPS)
Table S1 Association results for markers with local
ancestry-adjusted or –unadjusted p-values ,0.05. Case-
control association results are shown for the following loci: Chr
2q11.2, Chr 6p21.32, Chr 6q23.3 and Chr 17p13.1. Stage IV case
association results are shown for the following loci: Chr 2p12, Chr
10p11.23 and Chr 16q23.1.
(XLS)
Table S2 Number of variants analyzed by admixture
locus and imputation status.
(DOCX)
Table S3 Confirmation genotyping of imputed SNPs
rs62158012 (Chr 2p12–q12.1), rs6502976 (Chr 17p13.3–
13.1), rs6547087 (Chr 2p12–q12.3) and rs12919626 (Chr
16q21–23.2).
(DOCX)
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